Company intelligence / Profile preview

Aeras

Rockville, Maryland, United Statesaeras.tech ↗

Ownership: Private
Employees: ~65
Development stage: Other

Overview

Aeras was a leading nonprofit biotech focused on developing new and effective vaccines against tuberculosis. It advanced several vaccine candidates into clinical trials and maintained a robust early-stage portfolio. In 2018, the International AIDS Vaccine Initiative (IAVI) acquired its clinical programs and assets[3][4].

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Bill & Melinda Gates FoundationUK Department for International DevelopmentNetherlands’ Ministry of Foreign AffairsHuman Vaccines Project

Beyond the preview

Go deeper on Aeras.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aeras.

Explore the full profile